STE STERIS (STE) Q1 FY27 earnings call
STERIS delivered solid Q1 FY27 results with strong organic revenue growth and significant margin expansion, driven by pricing and productivity. The company announced a major $600 million investment in a new formulated chemistry center of excellence to support long-term growth and optimize its manufacturing network, while maintaining its full-year financial outlook. Management expects AST segment growth to accelerate in the second half of the fiscal year as inventory destocking subsides.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
STE operating KPIs by quarter
| KPI | Mar 2026 Q4 FY26 | This call Jun 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|
| Capital equipment backlog Healthcare | <$400MCapital equipment backlog ended just under $400 million with orders up 2% in the fourth quarter.Source: earnings call transcript | $444MOrders remained solid, with 4% growth in the first quarter, and our ending backlog increased to $444 million.Source: earnings call transcript | — |
| Capital equipment backlog Life Sciences | <$100MCapital equipment backlog ended solid at just under $100 million.Source: earnings call transcript | $110MBacklog at quarter end was about flat with prior year at $110 million.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.